Described as the industry's first and only high-throughput, high-resolution glycoanalysis platform, allowing the quantitative analysis of 20 samples in about three hours
PerkinElmer and Procognia have announced an exclusive distribution and co-marketing agreement to deliver what they say is the only complete solution for high-throughput and high-resolution analysis of the glycosylation of proteins. Procognia's U-c fingerprint lectin array-based platform is being combined with PerkinElmer's advanced instrumentation, the Protein Array Workstation and the recently introduced ProScanArray HT, to offer the industry's first high-throughput, high-resolution glycoanalysis capability. Certain scientific estimates indicate that more than 60% of critical biological functions involve glycosylated proteins.
This new technology will drive significant advancements in the understanding of protein function and structure.
U-c fingerprint technology requires no sample purification or pretreatment, and allows the quantitative analysis of 20 samples in approximately three hours.
In addition, glycosylation analysis throughout the therapeutic protein discovery, development and manufacturing process will bring biopharmaceutical companies closer to satisfying the FDA's Pat (process analytical technology) initiative.
This technology is focused on reducing the time and cost of producing higher quality biopharmaceuticals. "Procognia is a leader in proteomic technologies and together with PerkinElmer's extensive capabilities, we can now offer the industry's first complete high-throughput, high-resolution glycoanalysis platform for academic, biotech, and pharmaceutical customers," said Peter Coggins, president, PerkinElmer Life and Analytical Sciences.
"We believe we can accelerate adoption of Procognia's U-c fingerprint technology and firmly establish it as the gold standard in the monitoring and control of glycosylation of proteins by teaming with a global life sciences solutions provider like PerkinElmer," said Ron Long, CEO of Procognia.
